TABLE 2.
Characteristics of patients with pancreatic ductal adenocarcinoma (n = 50)
| Parameter | n = 50 |
|---|---|
| Age, y; median (range) | 71.5 (38‐85) |
| Sex, n (%) | |
| Male | 32 (64.0) |
| Female | 18 (36.0) |
| Preoperative CA19‐9, IU/mL; median (range) | 100 (1‐2392) |
| Neoadjuvant treatment, n (%) | 0 (0.0) |
| Induction of adjuvant treatment, n (%) | 42 (84.0) |
| Successfully completed adjuvant treatment, n (%) | 29 (58.0) |
| Regimen of adjuvant treatment, n (%) | |
| S‐1 | 26 (52.0) |
| Gemcitabine | 1 (2.0) |
| Gemcitabine + S‐1 | 2 (4.0) |
| Surgical procedure, n (%) | |
| Pancreaticoduodenectomy | 27 (54.0) |
| Distal pancreatectomy | 20 (40.0) |
| Total pancreatectomy | 3 (6.0) |
| Severe complications, n (%) | 7 (14.0) |
| Surgery‐related deaths, n (%) | 0 (0.0) |
| Tumor location, n (%) | |
| Head | 28 (56.0) |
| Body or tail | 22 (44.0) |
| Tumor size, mm; median (range) | 29.5 (12‐65) |
| Residual tumor status, n (%) a | |
| R0 | 29 (58.0) |
| R1 | 21 (42.0) |
| R2 | 0 (0.0) |
| Pathological T status, n (%) a | |
| pT1 | 7 (14.0) |
| pT2 | 35 (70.0) |
| pT3 | 8 (16.0) |
| pT4 | 0 (0.0) |
| Pathological N status, n (%) a | |
| pN0 | 10 (20.0) |
| pN1 | 21 (42.0) |
| pN2 | 19 (38.0) |
| Pathological stage, n (%) a | |
| IA | 4 (8.0) |
| IB | 6 (12.0) |
| IIA | 0 (0.0) |
| IIB | 20 (40.0) |
| III | 18 (36.0) |
| IV | 2 (4.0) |
CA19‐9, carbohydrate antigen 19‐9.
a
Based on UICC TNM classification (8th edition).